The mission of EMBL-EBI is to: provide freely available data and bioinformatics services to all facets of the scientific community in ways that promote scientific progress; contribute to the advancement of biology through basic investigator-driven research in bioinformatics; provide advanced bioinformatics training to scientists at all levels; and help disseminate cutting-edge technologies to industry. . The research and service activities of EMBL-EBI span the entire spectrum of life science and remain at the cutting edge of the computational sciences. All our major data resources are the products of international collaborations. We work with other data providers to ensure that our data repositories, and those of our collaborators, are comprehensive and up to date. We also actively participate in international efforts to develop data standards.. . The EMBL-EBI Industry Programme engages our industrial users with the latest bioinformatics research, service development, standards activities, pre-competitive opportunities and training https://www.ebi.ac.uk/industry.
Empyrean Therapeutics is focused on developing next generation off-the-shelf cell therapies to enable global and affordable cures for cancer and rare disease. We are building unique technologies, cellular assets and engineering processes which combine to deliver a powerful platform for rapidly manufacturing cellular drugs with novel disease fighting properties. . . Headquartered at the Babraham Research Campus, south of Cambridge, and working with leading clinical partners and academic experts, we are combining world class skills in gene editing with expertise in stem cell programming and precise genetic control to unlock the true potential of designer cellular medicines.
No data available
Immunotherapeutics company targeting a new class of tumour specific antigens
Essen BioScience is a world leader in the field of innovative cell-based assays, reagents, instrumentation and custom services for discovery research. Our specialities include phenotypic 'live content' kinetic imaging assays based around IncuCyte Zoom (e.g. angiogenesis, neurite outgrowth, cell migration/invasion, apoptosis etc.) and high throughput automated electrophysiology for ion channel drug discovery and safety (e.g. hERG assays). Our live content imaging solution has been adopted by laboratories across all 10 of the world’s top pharmaceutical companies as well as more than 150 leading biotechnology and academic research institutions.
Eurofins PSS® is part of Eurofins Scientific, an international life sciences company, providing a unique range of analytical testing services across multiple industries, through a network of over 900 laboratories in 62 countries, and c.a. 62,000 employees.
At Eurofins PSS Insourcing Solutions we hire Dedicated, full-time, and qualified Eurofins scientific staff working at client’s site using client’s facilities, equipment, computer systems, SOPs and methods
Our bespoke on-site management report to senior management at Eurofins PSS UK, ensuring service delivery and support, Comprehensive technical and client service training and leadership development to maximise talent with access to Eurofins in-house technical staff and resources
At Eurofins PSS Insourcing Solutions we hire Dedicated, full-time, and qualified Eurofins scientific staff working at client’s site using client’s facilities, equipment, computer systems, SOPs and methods
Our bespoke on-site management report to senior management at Eurofins PSS UK, ensuring service delivery and support, Comprehensive technical and client service training and leadership development to maximise talent with access to Eurofins in-house technical staff and resources
Selcia Ltd headquartered in Ongar, Essex, UK, is a leading worldwide provider of contract research services. Selcia Discovery provides integrated small molecule drug discovery, including general medicinal chemistry and biology capabilities, applicable across all target classes with a particular strength in three unique and highly synergistic technologies: (1) medicinal chemistry on complex natural products; (2) capillary electrophoresis-based fragment and natural product screening; and (3) peptidyl-prolyl isomerase targets (cyclophilins, FKBPs, Pin1, together called PPIases). Selcia Radiolabelling specialises in GMP radiolabelled API and in 14C custom radiolabelling for metabolism, distribution and environmental fate studies.
No data available
No data available
F-star is a clinical-stage biopharmaceutical company developing bispecific antibody immuno-oncology products selected for their potential to transform the treatment of cancer. Through the application of its highly efficient Modular Antibody Technology™ platform, F-star is the only biotechnology company able to create bispecific antibodies, where the second binding site is in the constant Fc region of an antibody, offering unprecedented ease in the discovery, development and manufacturing of bispecific antibody products. The strength of the technology and programmes has been leveraged through partnerships with leading biopharmaceutical companies including, AbbVie, Bristol-Myers Squibb, Merck Serono and Boehringer Ingelheim.. . For more information visit https://www.f-star.com